FIELD: biotechnology.
SUBSTANCE: conjugate for the 5T4 antibody or its antigen-binding fragment with monomethylauristatin F (MMAF), coupled through maleimidocaproyl; and a pharmaceutically acceptable salt thereof. Furthermore, a pharmaceutical composition is considered, a method of 5T4-positive cancer treatment and invention-based conjugate application for the drug manufacture. The method for conjugate production is described. According to this invention, the conjugate is at least 100 times less toxic than the 5T4 antibody conjugate with calicheamicin.
EFFECT: possibility of conjugate application for therapy.
17 cl, 17 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| HUMAN ANTIBODIES AND CONJUGATES OF ANTIBODY-PREPARATION AGAINST CD74 | 2012 |
|
RU2636029C2 |
| ANTI-5T4 ANTIBODIES AND USE THEREOF | 2007 |
|
RU2487889C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | 2015 |
|
RU2670157C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
